Primary central nervous system lymphoma (PCNSL) is a rare subtype of lymphoma that arises within the brain or the eyes. PCNSL recurs within the central nervous system (CNS) in most relapsed cases, whereas extra-CNS relapse is experienced in rare cases. The present study aimed at identifying the presence of common precur- 
| INTRODUC TI ON
Primary central nervous system lymphoma (PCNSL) is a rare form of diffuse large B-cell lymphoma (DLBCL) that arises within the brain or eyes. 1 Recent exome sequencing studies have shown that genes of the Toll-like receptor and B-cell receptor signaling pathways are frequently mutated in PCNSL. [2] [3] [4] Notably, the hotspot mutation of MYD88, which results in the conversion from leucine to proline at the 265th position (L265P MYD88 mutation), has a very high prevalence in patients with PCNSL (38%-85.4%). [2] [3] [4] [5] A previous report showed that the L265P MYD88 mutation, but not other mutations, found in PCNSL tumors was detected in peripheral blood mononuclear cells (PBMNC). 3 This may imply that the L265P MYD88 mutation may occur at the extra-central nervous system (CNS) compartment as the initial genetic event for PCNSL development. However, the actual developmental process of PCNSL should be examined from a different point of view.
Comparisons between genomic alterations in tumors at diagnosis and those at relapse led to the suggestion of common precursor cells (CPC) for the primary and relapsed tumors in other types of lymphoma such as follicular lymphomas (FL) and mantle cell lymphomas (MCL). 6, 7 Primary and relapsed tumors of FL and MCL may arise through a divergent evolution pattern from CPC by acquiring mutations specific to either primary or relapsed tumors. 6, 7 PCNSL recurs within the CNS in most relapsed cases, whereas extra-CNS relapse (systemic relapse) is experienced in <7% of the relapsed cases. 1 The present study aimed at identifying the presence of CPC with multiple mutations by examining paired primary intra-and relapsed extra-CNS tumors and further assessing the initiating events by examining MYD88 mutations in bone marrow mononuclear cells (BMMNC).
| MATERIAL S AND ME THODS

| Targeted deep sequencing by Ion Torrent PGM
Targeted deep sequencing (TDS) was carried out in five paired primary intra-CNS and relapsed extra-CNS tumors and BMMNC using the Lymphopanel for 34 candidate genes 8 and our in-house PCNSL panel for 12 candidate genes 1 (Tables S1 and S2 ). Because seven genes overlapped, 39 candidate genes were analyzed in total.
The mutational profiles of five primary intra-CNS tumors by our inhouse PCNSL panel were previously described. These mutations were validated by genomic PCR followed by Sanger sequencing. The primers are listed in Table S3 .
| Polymerase chain reaction detection of complementarity-determining region 3 region of Ig heavy chain genes
Polymerase chain reaction (PCR) for amplification of the complementarity-determining region 3 (CDR3) was carried out in a semi-nested approach. 9 The first step of PCR was carried out using primer FR2A or FR3A plus a reverse primer directed at the joining region (LJH). In the second step, the same forward primer (FR2A or PCR amplicons were extracted by using QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) and sequenced by direct sequencing.
Obtained sequences were analyzed using IMGT/V-QUEST from the international ImMunoGeneTics information system (IMGT) (http:// www.imgt.org). Tables S4 and S5 . In all five patients, first complete response (CR) was achieved during or at the end of the modified European Organisation for Research and Treatment of Cancer (EOTRC) chemotherapy for PCNSL 4 and was maintained for more than 1 year ( Figure S1 ). Subsequently, extra-CNS relapse occurred ( Figure S1 ). Median time from diagnosis of PCNSL to extra-CNS relapse was 18 months (Table S4) (Table S6 ). Quality of the extracted DNA from tumor samples was described as ΔΔCT based on the results of real-time quantitative PCR by using Agilent FFPE QC Kit (Agilent, Wilmington, USA) (Data S1). ΔΔCT of paired tumor samples varied from 0.01 to 0.76 (Table S7 ).
| Recurrently mutated genes in PCNSL patients
Targeted deep sequencing was carried out for 39 genes in five tumor pairs using the Lymphopanel 8 and our in-house PCNSL panel. Table S8 ). An aberrant somatic hypermutation (aSHM) indicator value was calculated according to the algorithm of Khodabakhshi et al. 12 The value was lower than 0.1, showing that PIM1 mutations were associated with aSHM (Data S1, Table S9 ). 
| Landscape of somatic mutations in primary intra-and relapsed extra-CNS tumors of PCNSL patients
We found shared mutations in all five paired tumors and unique mutations in all five intra-CNS tumors and in four out of five extra-CNS tumors (Figure 2 ). In total, 16 mutations in 11 genes were found to be shared (Figures 2 and 3 ; Table S8 ). MYD88 (4/5) mutations, L265P in three and P258L in one, were the most recurrently shared mutations. CD79B (3/5), KMT2D (3/5), and PIM1 (2/5) mutations also emerged as recurrently shared mutations, among which Y196 CD79B (3/5), and Q2951R KMT2D (2/5) were identified as hotspot mutations ( Figure 1 , Table S8 ). Forty-five mutations in six genes, including recurrent GNA13 and CREBBP mutations were specific to primary intra-CNS tumors. (Figures 2   and 3 ; Figure S2 , Table S8 ). Fifty-two mutations in six genes were specific to relapsed extra-CNS tumors (Figures 2 and 3 ; Figure S2 , Table S8 ).
| Divergent evolution of primary intra-and relapsed extra-CNS tumors from a CPC
These distribution patterns of shared and separated mutations strongly [13] [14] [15] [16] (Table S10 , Figure S3 ).
These analyses imply that the CPC is mapped at distinct positions in B-lineage differentiation; the position after IgH rearrangement and even after hypermutation at the variable region was suggested in T1, whereas emergence of CPC before IgH rearrangement was suggested in T5 and TP39.
| Detection of L265P MYD88 mutations in BMMNC or PBMNC with droplet digital PCR
To further characterize the initiation of PCNSL that is theorized to precede the emergence of CPC, we analyzed PBMNC of T1 collected at the diagnosis of extra-CNS relapse and BMMNC of T1, T2, T5
and 20 PCNSL patients in an extended cohort collected at diagnosis (N = 24). These 24 cases were those in whom the L265P MYD88 mutations were identified in primary PCNSL tumors. According to the pathological diagnosis, no clinical evidence of lymphoma infiltration was found in the bone marrow (BM) of these patients. The L265P
MYD88 mutations were identified in PBMNC (T1) and in nine out of 23 BMMNC (in total, 10 of 24) by droplet digital PCR (ddPCR), whereas the mutations were not detected in any of the samples by TDS, a less sensitive method ( Figure S4 , Table S11 ).
| D ISCUSS I ON
This is the first multidimensional study of mutational dynamics comparing mutational profiles between intra-CNS tumors and extra-CNS tumors. In our study, all the five paired tumors shared multiple mutations. Unique somatic mutations were observed in all the five intra-CNS tumors and four out of five extra-CNS tumors (Table S8 , Figure S2 ). Among the somatic mutations specific to intra-CNS tumors, TBL1XR1 mutation was reported to be more prevalent in PCNSL than in DLBCL not otherwise specified (NOS). 17 In contrast, a SOCS1 mutation was detected in the tumor of subcutaneous tissue in TP44 (Table S4) . SOCS1 mutations are known to be more prevalent in primary cutaneous diffuse large B-cell lymphoma, leg type compared to DLBCL NOS. 18 Therefore, somatic mutations in these genes may bias the location of tumors. These results suggest that the paired tumors originate from divergent evolution of CPC through accumulation of distinct mutations.
Recent studies have proposed that primary and relapsed tumors in several hematological cancers may arise from CPC. 6, 7, [18] [19] [20] Previously, it was reported that the dominant clones were identical in paired tumors of primary and relapsed MCL and FL according to the VDJ coding joints, suggesting that CPC may arise after F I G U R E 6 Stages of divergence from common precursor cells to tumors. Black arrows indicate the clonal pathway between samples. CLL, chronic lymphocytic leukemia; CNS, central nervous system; FL, follicular lymphoma; MCL, mantle cell lymphoma; PCNSL, primary central nervous system lymphoma VDJ rearrangement ( Figure 6 ). 6, 7 In contrast, in a part of Richter syndrome, distinct IgH clones were observed between aggressive lymphomas and primary chronic lymphocytic leukemia (CLL) tumors suggesting that divergence may occur before the VDJ rearrangements. 19, 20 In the current study, the existence of identical monoclonal B-cell clones in both intra-and extra-CNS tumors of T1 suggests that divergence from CPC could occur after the point of IgH rearrangement, similar to the case of FL and MCL ( Figure 6 ). In contrast, distinct IgH clones were observed in the intra-and extra-CNS tumors of patients T5 and TP39, which suggests that divergence of CPC could occur preceding a VDJ rearrangement in BM, similar to the case of Richter syndrome in CLL ( Figure 6 ). 19, 20 In a previous analysis, tumorrelated IgH clones were detected in blood and bone marrow of three PCNSL patients. 21 These results suggest that divergence from the CPC could occur after the point of IgH rearrangement in all of these patients, although hypermutations occurred independently in IgH clones of primary tumors in the CNS and in those in the systemic sites. 21 This pattern is similar to the case of patient T1 in our study in which identical monoclonal B-cell clones existed in both intra-and extra-CNS tumors, although independent hypermutations were not observed in these tumors. In contrast, the findings in patients T5 and TP39 were remarkable because VDJ usage was different between intra-and extra-CNS tumors in these two patients.
It has been suggested that, in FL and MCL, the initial genetic NOTCH1 and SF3B1 mutations in CLL, 22 BRAF mutations in hairy cell leukemia 23 and TET2/DNMT3A mutations in angioimmunoblastic T-cell lymphomas. [24] [25] [26] Frequent detection of L265P MYD88 mutation in BM suggests that, in PCNSL patients, this mutation may occur before or during the B-cell differentiation process before the cells leave the BM environment and migrate to the peripheral lymphoid organs as naïve mature B lymphocytes. This theory, however, needs further proof because the presence of minimal contamination of lymphoma cells in the BM was not completely excluded in our study, although the presence of lymphoma cells was excluded by immunohistochemical evaluation and flow cytometry. Additionally, we were unable to examine the L265P MYD88 mutation in healthy individuals. The L265P MYD88 mutation was detected in PBMNC of only one subject at a mutation allele frequency of 23% in a cohort of 12 380 patients with psychiatric disease. 27 This mutation was undetected in that of any subject in another large cohort of 17 182 individuals without hematological malignancies. 28 Because the cutoff levels of mutation allele frequencies in both studies were 2%, smaller allele frequencies could have escaped detection and, therefore, the possibility cannot be completely excluded that very few cells with L265P MYD88 are present even in healthy individuals.
In conclusion, our data suggest that intra-and extra-CNS tumors might originate from the CPC in PCNSL. The initial event could be a mutation in the MYD88 gene, and the emergence of CPC might follow by acquisition of subsequent genetic alterations. Precise clarification of these steps may contribute to establishing more robust biomarkers and therapeutic approaches with newly developed targeted drugs. 
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